ArticleCancer management and research2021
Use of Skin Testing Screening and Desensitization Before the First Exposure of Rituximab.
Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 citations in OpenAlex.
- Real‑world pharmacovigilance of rituximab‑associated adverse reactions in children and adolescents: Disproportionality signal detection and time‑to‑onset pattern characterization using the FAERS database.Human vaccines & immunotherapeutics · 2026Article
- Skin Testing for the Detection of Rituximab Hypersensitivity in a Pediatric Case of Pemphigus Vulgaris.International journal of dermatology · 2026Article
- Sequential anaphylaxis and delayed rituximab-induced serum sickness with skin testing findings: a case report.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026Article
- Management of Rituximab-Associated Hypersensitivity Reactions with Successfully Applied Desensitization Protocols: A Clinical Experience of 46 Infusions in 11 Patients.Journal of clinical medicine · 2026Article
- The role of circular RNAs in mediating the protective effects of exercise against muscle degeneration and aging.Biogerontology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the incidence and severity of immediate hypersensitivity reactions (HSRs) in the first exposure to rituximab with the adoption of skin testing screening and desensitization and investigate the value of skin testing as a predictive tool for immediate HSR to rituximab.
methodsThis was a prospective intervention study. Patients with hematological malignancies who required rituximab were recruited. Skin testing screening with rituximab was conducted before the first infusion. Patients with positive skin testing results underwent desensitization, while those with negative results received rituximab at a standard infusion rate. All immediate HSRs were recorded, and the predictive value of positive skin testing results for immediate HSRs to rituximab was analyzed.
resultsIn the 19 patients who adopted the novel protocol, six patients (31.6%) had immediate HSRs during the first infusion, with three mild reactions (15.8%), two moderate reactions (10.5%), and only one severe reaction (5.3%). The positive predictive value of intradermal test (IDT) with 1 mg/mL rituximab solution for immediate HSR was 100%, and the negative predictive value was 84.6%.
conclusionThe protocol of skin testing screening and desensitization might have some potential to control the incidence and severity of immediate HSRs to rituximab during the first exposure. IDT result before the first infusion could become a useful predictor for immediate HSR to rituximab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.